Ovarian

Mainstreaming Genetic Counselling for Ovarian Cancer Could Support Screening, in Malaysia and Beyond

(ESMO Asia 2017 Congress) Nov 17, 2017 - A study that looked at mainstreaming genetic counselling for ovarian cancer to support screening programmes in Malaysia was presented at the ESMO Asia 2017 Congress.

read press release

ASPiRA Labs Announces Release of Final CMS Reimbursement Rate for OVA1

(Business Insider) Nov 20, 2017 - ASPiRA Labs, a Vermillion company and the exclusive distributor of OVA1 (Multivariate Index Assay) (MIA), and Overa (MIA2G), today announced that the Center for Medicare Services (CMS) has released the Final 2018 Clinical Lab Fee Schedule, effective January 1, 2018.

read article

OncoQuest Announces Collaboration with TESARO in Recurrent Ovarian Cancer Setting

(Business Insider) Nov 2, 2017 - OncoQuest Inc., a biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer, today announced the signing of a collaborative agreement with TESARO, Inc. to conduct a proof-of-concept clinical trial evaluating the combination of oregovomab with ZEJULA® (niraparib) in the recurrent ovarian cancer setting.

read article

iPharma Enters Into Licensing Agreement With Boehringer Ingelheim to Obtain Worldwide Rights to FAK Inhibitor Oncology Development Program

(The Business Journals) Nov 2, 2017 - iPharma Ltd., a global biotech company focusing on the development of innovative immune oncology therapies, announced today that it has entered into an exclusive worldwide license agreement with Boehringer Ingelheim, one of the global pharmaceutical industry's top 20 companies, to manufacture, develop, and commercialize BI 853520, a focal adhesion kinase inhibitor (FAKi).

read article

New Blood Test Detects Early Resistance To BRCA-targeting Drugs For Breast And Ovarian Cancer

(ICR [UK]) Nov 2, 2017 - Scientists have developed a new highly sensitive blood test to deliver precision medicine to women with BRCA mutations who have breast or ovarian cancer.

read article

New Blood Test Developed to Diagnose Ovarian Cancer

(Dana-Farber Cancer Institute) Oct 31, 2017 - Investigators from Dana-Farber Cancer Institute and Brigham and Women's Hospital (BWH) are leveraging the power of artificial intelligence to develop a new technique to detect ovarian cancer early and accurately.

read press release

OncoQuest Announces Collaboration with TESARO in Recurrent Ovarian Cancer Setting

(OncoQuest) Oct 26, 2017 - OncoQuest Inc., a biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer, today announced the signing of a collaborative agreement with TESARO, Inc. to conduct a proof-of-concept clinical trial evaluating the combination of oregovomab with ZEJULA® (niraparib) in the recurrent ovarian cancer setting.

read corporate press release

Mutation in Fallopian Tube Lesions May Help Catch Ovarian Cancer Years Earlier

(Penn Medicine) Oct 26, 2017 - Screening for tumor cells in the fallopian tubes of women at high-risk for ovarian cancer may help detect the cancer years before it develops further, suggests a new study co-led by researchers at Penn Medicine and published online this week in Nature Communications.

read press release

FDA Accepts Genentech’s Supplemental Biologics License Application For Avastin As A Front-Line Treatment For Women With Advanced Ovarian Cancer

(Genentech) Oct 25, 2017 - Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin alone, for the front-line treatment of women with advanced ovarian cancer.

read corporate press release

J&J Wins Reversal of $417 Million California Talc Verdict

(Bloomberg) Oct 20, 2017 - Johnson & Johnson got a $417 million jury verdict thrown out after a California judge agreed the company didn’t have a duty to warn a woman who has since died that its Baby Powder could cause ovarian cancer.

read article

Astra And Merck Win Speedy Review For Lynparza In Breast Cancer

(Reuters) Oct 18, 2017 - U.S. regulators have granted a priority review to AstraZeneca’s ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018.

read article

J&J Wins Reversal Of First St. Louis Talc-Cancer Verdict

(Bloomberg) Oct 17, 2017 - Johnson & Johnson won its appeal of a $72 million verdict claiming its talc products cause ovarian cancer, as a Missouri appeals court found the case shouldn’t have been tried in a St. Louis city court.

read article

Johnson & Johnson Wins Reversal Of $72 Million Verdict Over Talc Cancer Risks

(Reuters) Oct 17, 2017 - Johnson & Johnson on Tuesday won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company’s talc-based products like Johnson’s Baby Powder.

read article

Many Pelvic Tumors in Women May Have Common Origin: Fallopian Tubes

(NYU Langone Health) Oct 18, 2017 - Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes to which they are attached.

read press release

Stand Up To Cancer Catalyst® Launches 10 Clinical Trial Projects Combining Cancer Treatments from Nine Different Pharmaceutical Companies to Explore Innovative Approaches and Find New Indications for Blockbuster Drugs to Improve Patient Outcomes

(AACR) Oct 12, 2017 - Stand Up To Cancer (SU2C) has awarded 10 SU2C Catalyst® clinical trial projects in which researchers from more than 30 institutions collaborate across academic and corporate borders on clinical trials – with correlated translational research which will deepen our understanding of why treatments are effective – across a variety of cancers, in a program supported by industry.

read press release

Study: Don’t Delay Platinum Re-Challenge in Ovarian Cancer

(MedPage Today) Oct 11, 2017 - Don't delay platinum-based chemotherapy in favor of single-agent non-platinum-based chemotherapy in patients with partially platinum-sensitive ovarian cancer, Italian researchers advised.

read article (free registration required)

Immune Response To Ovarian Cancer May Predict Survival, Mayo-Led Study Finds

(Mayo Clinic) Oct 12, 2017 - A group of international cancer researchers led by investigators from Mayo Clinic and University of New South Wales Sydney has found that the level of a type of white blood cell, called tumor-infiltrating lymphocytes, present in the tumors of patients with high-grade ovarian cancer may predict a patient’s survival.

read article

Clovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients with Platinum-Sensitive Recurrent Ovarian Cancer

(Yahoo! Finance) Oct 9, 2017 - Clovis Oncology announced today that the company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for rucaparib as maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

read article

The FDA Is Approving Drugs at a Staggering Pace

(Bloomberg) Oct 6, 2017 - The U.S Food and Drug Administration, under Commissioner Scott Gottlieb, is taking advantage of policy groundwork laid in past years to speed drug approvals. Thirty-four new drugs -- treating everything from cancer to rare genetic diseases -- have been approved so far this year.

read article

Cancers Associated with Overweight and Obesity Make up 40 percent of Cancers Diagnosed in the United States

(CDC) Oct 3, 2017 - Overweight and obesity are associated with increased risk of 13 types of cancer. These cancers account for about 40 percent of all cancers diagnosed in the United States in 2014, according to the latest Vital Signs report by the Centers for Disease Control and Prevention (CDC).

read press release
Next Page